ICPT Insider Trading Activity and SEC Form 4 Filings
ICPT insider trading summary
No open-market insider purchases or sales of Intercept Pharmaceuticals, Inc. (ICPT) have been reported on SEC Form 4 in the past 12 months.
Latest ICPT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 12, 2021 | Srinivas Akkaraju | Director | Buy | $3.1M (147,000 @ $21.29) |
| Mar 10, 2021 | Srinivas Akkaraju | Director | Buy | $357K (16,559 @ $21.55) |
| Mar 10, 2021 | Srinivas Akkaraju | Director | Buy | $1.5M (73,441 @ $20.83) |
| Jan 5, 2021 | Sandip Kapadia | CFO and Treasurer | Sell | $54K (2,193 @ $24.47) |
| Dec 15, 2020 | Sandip Kapadia | CFO and Treasurer | Sell | $58K (1,763 @ $32.78) |
| Aug 18, 2020 | Jason Campagna | Chief Medical Officer | Sell | $57K (1,192 @ $47.44) |
| Aug 17, 2020 | S.p.A. Genextra | Insider | Sell | $6.4M (126,888 @ $50.15) |
| Aug 17, 2020 | Paolo Fundaro | Insider | Sell | $6.4M (126,888 @ $50.15) |
| Aug 17, 2020 | Francesco Micheli | Insider | Sell | $6.4M (126,888 @ $50.15) |
| Aug 17, 2020 | S.p.A. Genextra | Insider | Sell | $57.8M (1,235,512 @ $46.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.